In short
Clinical trials investigating Sodium Nitrite are studying its use in people with non-cystic fibrosis bronchiectasis and harmful airway bacteria. These studies mainly look at safety, tolerability, and early signs of benefit in adults with confirmed respiratory infection. The trial data here focus on how the treatment is tested, who may take part, and which outcomes are measured.
Key points
- Sodium Nitrite is being studied in a Phase 1 clinical trial in people with non-cystic fibrosis bronchiectasis and harmful airway bacteria. The trial is completed and included 67 participants. Researchers mainly looked at safety, tolerability, blood test changes, and vital signs. The main condition studied was bronchiectasis with Pseudomonas aeruginosa or other potentially pathogenic micro-organisms. This trial helps show whether the treatment can be studied further in this patient group.
Trial overview
The source data describe one interventional clinical trial investigating Sodium Nitrite in a respiratory setting, although the study title uses the name RESP30X and includes inhaled formulations. The trial was designed to assess safety and tolerability in people with non-cystic fibrosis bronchiectasis and confirmed high-titre respiratory potentially pathogenic micro-organisms.
This study was completed and enrolled 67 participants.
Who was studied
The target population was people with non-cystic fibrosis bronchiectasis, which is a long-term lung condition where the airways are damaged and widened.
The study also required confirmed high-titre respiratory potentially pathogenic micro-organisms (PPMs), including Pseudomonas aeruginosa or other similar germs that may cause disease.
In simple terms, the trial focused on people who had both a chronic lung problem and evidence of harmful bacteria in the airways.
What was tested in the trial
The interventions listed in the source data were RESP302, salbutamol, and RESP303, all given by inhalation use.
The brief summary says the study aimed to assess the safety and tolerability of RESP30X in participants with confirmed high-titre respiratory PPMs.
Safety means looking for unwanted health problems, while tolerability means how well people can receive the treatment without major difficulty.
Outcomes measured
The primary outcomes included the incidence, intensity, causality, and seriousness of treatment-emergent adverse events (TEAEs).
TEAEs are health problems that begin or become worse after treatment starts.
Researchers also measured changes in laboratory values, including haematology and clinical chemistry, at each time point.
They further tracked changes in vital signs such as blood pressure, heart rate, temperature, respiratory rate, and oxygen saturation (SpO2).
Trial phase and status
This was a Phase 1 trial, which is an early stage of clinical research that mainly checks safety and tolerability.
The study status is listed as completed, so the planned testing and data collection were finished.
What the trial means for patients
For patients, this trial shows that Sodium Nitrite was being explored in a small early study for a specific lung condition linked to airway bacteria.
The main question was not whether the treatment cures disease, but whether it can be studied safely in this group and what short-term changes appear in tests and vital signs.
Because the study was completed, its data can help researchers decide whether larger studies should be done later.